Washington DC
,
USA
7 - 10 November 2025
American Association for the Study of Liver Diseases (AASLD 2025)
Presentation schedule and materials
Saturday, 08 November 2025
13:00
- 14:00
ET
2570
POSTER
Comparing the Risk of Major Adverse Cardiovascular and Liver Outcomes in Patients with Probable MASH to those with Diagnosed MASH and Without MASH
Caichen Zhong1; Nana Boame2; Semiu O. Gbadamosi1; Maximilian Jara1; Rakesh Luthra1; Yu Hong2; Bret Zeldow2; Abdalla Ally1; Mary E. Rinella3
MATERIALS AVAILABLE
13:00
- 14:00
ET
2625
POSTER
Real-world prevalence of diagnosed metabolic dysfunction-associated steatohepatitis among Medicare beneficiaries
Husam Albarmawi1; Abdalla Aly1; Anthony Hoovler1; Caichen Zhong1; Anran Tan2; Jamieson Vaccaro2; Joanna Harton2; Parvez Mantry3
MATERIALS AVAILABLE
13:00
- 14:00
ET
2545
POSTER
Risk of microvascular and macrovascular complications in patients with type 2 diabetes and cirrhotic metabolic dysfunction-associated steatohepatitis: a retrospective cohort study
Semiu O Gbadamosi1; David Shi1; Abdalla Aly1; Caichen Zhong1; Husam Albarmawi1; Aidan McGovern1; Anthony Hoovler1; Carlos Campos2
MATERIALS AVAILABLE
13:00
- 14:00
ET
2075
POSTER
SomaSignal defined MASH disease components are prognostic of secondary cardiovascular disease – A post-hoc analysis of the SELECT trial
Arun J. Sanyal1; Steen Ladelund2; Michelle T. Long2; Sune Boris Nygård2; Adel Belloum2; Jörn M. Schattenberg3
MATERIALS AVAILABLE
13:00
- 14:00
ET
2052
POSTER
Prevalence of steatosis and liver fibrosis in patients with SUSPECTED MASLD/MASH from non-hepatology centers in the USA and Europe
Jörn Schattenberg1; Julie Foucquier2; Mamta Upadhyay3; Kwabena Opuni4; Victor de Lédinghen2; K. Cusi5
MATERIALS AVAILABLE
Sunday, 09 November 2025
13:00
- 14:00
ET
3086
POSTER
A qualitative study exploring the experiences and unmet needs of patients living with metabolic dysfunction-associated steatohepatitis
Ahsan Shoeb Patel1; Jannie Laursen1; Nathalie Marcela Eklöf1
MATERIALS AVAILABLE
Monday, 10 November 2025
08:45
- 09:00
ET
0010
ORAL PRESENTATION
Weight-dependent and independent effects of semaglutide in participants with MASH: secondary analysis of the phase 3 ESSENCE trial
Philip N. Newsome1,2; Matthew J. Armstrong3; Igor Bakulin4; Adel Belloum5; Anja Geerts6,7; Jacob George8; Ewa Janczewska9; Niels Krarup5; Chun-Jen Liu10,11; Håvard Midgard12; Kwabena Opuni5; Vlad Ratziu13; Mary Rinella14; Michael Roden15,16,17; Arun J. Sanyal18; Jörn Schattenberg19; Thea Vestergaard5; Elisabetta Bugianesi20, on behalf of the ESSENCE Study Group
MATERIALS AVAILABLE
13:00
- 14:00
ET
4042
POSTER
Semaglutide is effective in improving liver fibrosis across a diverse population: ESSENCE subgroup analysis
Mary E. Rinella1; Manal F. Abdelmalek2; Elisabetta Bugianesi3; Laurent Castera4,5; Mette Skalshøi Kjær6; Jacob George7; Wah Kheong Chan8; Niels Krarup6; Michelle T. Long6; Philip N. Newsome9,10; Cláudia P. Oliveira11; Georgios Papatheodoridis12; Ahsan Shoeb6; Salvatore Petta13; Michael Roden14,15,16; Arun J. Sanyal17; Yusuf Yilmaz18; Vlad Ratziu19; on behalf of the ESSENCE Trial Group
MATERIALS AVAILABLE
13:00
- 14:00
ET
5037
POSTER
HbA1c-independent benefits of semaglutide on liver histology and non-invasive tests in participants with biopsy-defined MASH: insights from post-hoc analysis of the ESSENCE trial part 1
A.J. Sanyal1; E. Bugianesi2; T. Arias-Loste3; L. Castera4; N.M. Eklöf5; W. Kim6; N. Krarup5; B. Ludvik7; P.N. Newsome8; V. Ratziu9; M.E. Rinella10; A. Trifan11; T.C. Vestergaard5; M. Roden12; ESSENCE study group
MATERIALS AVAILABLE
14:45
- 15:00
ET
0174
ORAL PRESENTATION
Real-world Clinical and Economic Outcomes by Fibrosis Stage in Patients with Metabolic Dysfunction–Associated Steatohepatitis (MASH)
Prachi Arora1; Subash C2; Patrick Lenehan2; Jason K. Maron2; Abdalla Aly1; Maximilian Kurt Jara1; Rakesh Luthra1; Manal F. Abdelmalek3
MATERIALS AVAILABLE
Keywords